Abstract
Aim: To estimate neutralizing antibody (NAb) immunity against SARS-CoV-2 in 739 healthcare personnel (HCP) vaccinated with three doses of BNT162b2 mRNA vaccine.
Methods: Serum samples were collected at 3, 6, and 9 months after the second vaccine dose and at 7-55 days after the third dose. Samples were tested for NAbs against SARS-CoV-2 receptor binding domain.
Results: The mean inhibition rates at 3, 6, and 9 months after the second dose were 86.33%, 73.38%, and 61.18%, and increased to 95.57% after the booster dose. Younger HCP and HCP with past SARS-CoV-2 infection had higher inhibition rates while there was an inverse correlation between NAb levels and comorbidities or tobacco use (p-values < 0.001). Increased NAb titers were also noticed in women (p-value = 0.033), especially at the end of the 9-month study period.
Conclusion: NAb levels increased considerably after a booster mRNA vaccine dose. Host factors and past SARS-CoV-2 infection influence NAb titers.
Keywords: COVID-19; Healthcare personnel; Neutralizing antibodies; SARS-CoV-2; mRNA vaccine.
【저자키워드】 COVID-19, SARS-CoV-2, Neutralizing antibodies, mRNA vaccine, healthcare personnel, 【초록키워드】 neutralizing antibody, Immunity, mRNA vaccine, SARS-COV-2 infection, Comorbidity, SARS-CoV-2 receptor, vaccine dose, women, booster dose, booster, NAb, dose, Factor, second dose, study period, binding domain, inverse correlation, NAb titers, serum sample, hcp, NAb titer, tested, collected, Sample, Increased, of BNT162b2, 【제목키워드】 SARS-COV-2 infection, Antibody Response, mRNA BNT162b2 vaccine, association, dose, baseline characteristics,